Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer

JACC: CardioOncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles